0	9	Molecular	molecular	JJ
10	15	basis	basis	NN
16	18	of	of	IN
19	20	a	a	DT
21	29	multiple	multiple	JJ
30	40	lymphokine	lymphokine	NN
41	51	deficiency	deficiency	NN
52	54	in	in	IN
55	56	a	a	DT
57	64	patient	patient	NN
65	69	with	with	IN
70	76	severe	severe	JJ
77	85	combined	combined	JJ
86	102	immunodeficiency	immunodeficiency	NN
102	103	.	.	.

105	107	We	we	PRP
108	112	have	have	VBP
113	123	previously	previously	RB
124	132	reported	report	VBN
133	137	that	that	IN
138	141	the	the	DT
142	143	T	t	NN
144	155	lymphocytes	lymphocyte	NNS
156	158	of	of	IN
159	160	a	a	DT
161	166	child	child	NN
167	171	with	with	IN
172	178	severe	severe	JJ
179	187	combined	combined	JJ
188	204	immunodeficiency	immunodeficiency	NN
205	208	are	be	VBP
209	218	defective	defective	JJ
219	221	in	in	IN
222	225	the	the	DT
226	239	transcription	transcription	NN
240	242	of	of	IN
243	250	several	several	JJ
251	261	lymphokine	lymphokine	NN
262	267	genes	gene	NNS
268	272	that	that	WDT
273	280	include	include	VBP
281	284	IL2	il2	NN
284	285	,	,	,
286	289	IL3	IL3	NNP
289	290	,	,	,
291	294	IL4	IL4	NNP
294	295	,	,	,
296	299	and	and	CC
300	303	IL5	IL5	NNP
303	304	,	,	,
305	310	which	which	WDT
311	317	encode	encode	VBP
318	330	interleukins	interleukin	NNS
331	332	2	2	CD
332	333	,	,	,
334	335	3	3	CD
335	336	,	,	,
337	338	4	4	CD
338	339	,	,	,
340	343	and	and	CC
344	345	5	5	CD
346	347	(	(	(
347	351	IL-2	IL-2	NNP
351	352	,	,	,
353	355	-3	-3	CD
355	356	,	,	,
357	359	-4	-4	CD
359	360	,	,	,
361	364	and	and	CC
365	367	-5	-5	CD
367	368	)	)	)
368	369	.	.	.

370	372	To	to	TO
373	382	determine	determine	VB
383	390	whether	whether	IN
391	394	the	the	DT
395	401	defect	defect	NN
402	404	in	in	IN
405	408	the	the	DT
409	416	patient	patient	NN
416	418	’s	's	POS
419	420	T	t	NN
421	432	lymphocytes	lymphocyte	NNS
433	441	involved	involve	VBD
442	443	a	a	DT
444	456	trans-acting	trans-acting	JJ
457	463	factor	factor	NN
464	470	common	common	JJ
471	473	to	to	TO
474	477	the	the	DT
478	486	affected	affect	VBN
487	497	lymphokine	lymphokine	NN
498	503	genes	gene	NNS
503	504	,	,	,
505	507	we	we	PRP
508	516	examined	examine	VBD
517	520	the	the	DT
521	528	ability	ability	NN
529	531	of	of	IN
532	539	nuclear	nuclear	JJ
540	547	factors	factor	NNS
548	552	from	from	IN
553	556	the	the	DT
557	564	patient	patient	NN
564	566	’s	's	POS
567	568	T	t	NN
569	580	lymphocytes	lymphocyte	NNS
581	583	to	to	TO
584	588	bind	bind	VB
589	597	response	response	NN
598	606	elements	element	NNS
607	614	present	present	JJ
615	617	in	in	IN
618	621	the	the	DT
622	632	regulatory	regulatory	JJ
633	639	region	region	NN
640	642	of	of	IN
643	646	IL2	il2	NN
646	647	.	.	.

648	655	Nuclear	nuclear	JJ
656	662	factor	factor	NN
663	668	NF-kB	NF-kB	NNP
668	669	,	,	,
670	680	activation	activation	NN
681	688	protein	protein	NN
689	690	1	1	CD
691	692	(	(	(
692	696	AP-1	ap-1	NN
696	697	)	)	)
697	698	,	,	,
699	704	OCT-1	OCT-1	NNP
704	705	,	,	,
706	709	and	and	CC
710	718	NF-IL-2B	NF-IL-2B	NNP
719	726	binding	binding	NN
727	735	activity	activity	NN
736	740	were	be	VBD
741	747	normal	normal	JJ
747	748	.	.	.

749	751	In	in	IN
752	760	contrast	contrast	NN
760	761	,	,	,
762	765	the	the	DT
766	773	binding	binding	NN
774	776	of	of	IN
777	780	the	the	DT
781	788	nuclear	nuclear	JJ
789	795	factor	factor	NN
796	798	of	of	IN
799	808	activated	activate	VBN
809	810	T	t	NN
811	816	cells	cell	NNS
817	818	(	(	(
818	823	NF-AT	NF-AT	NNP
823	824	)	)	)
825	827	to	to	TO
828	831	its	its	PRP$
832	840	response	response	NN
841	848	element	element	NN
849	851	in	in	IN
852	855	the	the	DT
856	859	IL2	il2	NN
860	868	enhancer	enhancer	NN
869	872	and	and	CC
873	875	to	to	TO
876	878	an	an	DT
879	889	NF-AT-like	nf-at-like	JJ
890	898	response	response	NN
899	906	element	element	NN
907	914	present	present	JJ
915	917	in	in	IN
918	921	the	the	DT
922	925	IL4	il4	NN
926	934	enhancer	enhancer	NN
935	938	was	be	VBD
939	947	abnormal	abnormal	JJ
947	948	.	.	.

949	951	To	to	TO
952	961	ascertain	ascertain	VB
962	969	whether	whether	IN
970	973	the	the	DT
974	982	abnormal	abnormal	JJ
983	988	NF-AT	nf-at	NN
989	996	binding	binding	NN
997	1005	activity	activity	NN
1006	1009	was	be	VBD
1010	1017	related	relate	VBN
1018	1020	to	to	TO
1021	1023	an	an	DT
1024	1032	impaired	impaired	JJ
1033	1041	function	function	NN
1041	1042	,	,	,
1043	1045	we	we	PRP
1046	1057	transfected	transfecte	VBD
1058	1065	patient	patient	NN
1066	1069	and	and	CC
1070	1077	control	control	NN
1078	1079	T	t	NN
1080	1091	lymphocytes	lymphocyte	NNS
1092	1096	with	with	IN
1097	1107	constructs	construct	NNS
1108	1118	containing	contain	VBG
1119	1122	the	the	DT
1123	1131	reporter	reporter	NN
1132	1136	gene	gene	NN
1137	1145	encoding	encode	VBG
1146	1161	chloramphenicol	chloramphenicol	NN
1162	1168	acetyl	acetyl	NN
1169	1180	transferase	transferase	NN
1181	1182	(	(	(
1182	1185	CAT	CAT	NNP
1185	1186	)	)	)
1187	1192	under	under	IN
1193	1196	the	the	DT
1197	1204	control	control	NN
1205	1207	of	of	IN
1208	1211	the	the	DT
1212	1218	entire	entire	JJ
1219	1222	IL2	il2	NN
1223	1233	regulatory	regulatory	JJ
1234	1240	region	region	NN
1241	1243	or	or	CC
1244	1246	of	of	IN
1247	1256	multimers	multimer	NNS
1257	1259	of	of	IN
1260	1270	individual	individual	JJ
1271	1279	enhancer	enhancer	NN
1280	1289	sequences	sequence	NNS
1289	1290	.	.	.

1291	1294	CAT	CAT	NNP
1295	1305	expression	expression	NN
1306	1314	directed	direct	VBN
1315	1317	by	by	IN
1318	1321	the	the	DT
1322	1325	IL2	il2	NN
1326	1336	regulatory	regulatory	JJ
1337	1343	region	region	NN
1344	1346	or	or	CC
1347	1349	by	by	IN
1350	1351	a	a	DT
1352	1360	multimer	multimer	NN
1361	1363	of	of	IN
1364	1367	the	the	DT
1368	1381	NF-AT-binding	nf-at-binding	JJ
1382	1386	site	site	NN
1387	1390	was	be	VBD
1391	1399	markedly	markedly	RB
1400	1405	lower	low	JJR
1406	1408	in	in	IN
1409	1412	the	the	DT
1413	1420	patient	patient	NN
1421	1429	relative	relative	JJ
1430	1432	to	to	TO
1433	1441	controls	control	NNS
1441	1442	.	.	.

1443	1445	In	in	IN
1446	1454	contrast	contrast	NN
1454	1455	,	,	,
1456	1459	CAT	CAT	NNP
1460	1464	gene	gene	NN
1465	1475	expression	expression	NN
1476	1484	directed	direct	VBN
1485	1487	by	by	IN
1488	1489	a	a	DT
1490	1498	multimer	multimer	NN
1499	1501	of	of	IN
1502	1505	the	the	DT
1506	1511	OCT-1	oct-1	NN
1512	1520	proximal	proximal	JJ
1521	1522	(	(	(
1522	1537	OCT-1p)-binding	oct-1p)-binding	JJ
1538	1542	site	site	NN
1543	1546	was	be	VBD
1547	1557	equivalent	equivalent	JJ
1558	1560	in	in	IN
1561	1568	patient	patient	NN
1569	1572	and	and	CC
1573	1581	controls	control	NNS
1581	1582	.	.	.

1583	1588	These	these	DT
1589	1596	results	result	NNS
1597	1605	indicate	indicate	VBP
1606	1610	that	that	IN
1611	1613	an	an	DT
1614	1625	abnormality	abnormality	NN
1626	1631	of/or	of/or	IN
1632	1643	influencing	influence	VBG
1644	1649	NF-AT	NF-AT	NNP
1650	1653	may	may	MD
1654	1662	underlie	underlie	VB
1663	1666	the	the	DT
1667	1675	multiple	multiple	JJ
1676	1686	lymphokine	lymphokine	NN
1687	1697	deficiency	deficiency	NN
1698	1700	in	in	IN
1701	1705	this	this	DT
1706	1713	patient	patient	NN
1713	1714	.	.	.